Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

Citations Over TimeTop 12% of 2006 papers

Abstract

A series of highly selective irreversible inhibitors for Bruton's tyrosine kinase (Btk) was developed using a structural bioinformatics approach. Their capabilities to modulate Btk's activity were characterized both in vitro and in vivo. Oral treatment with once-a-day dosing of compound 4 greatly inhibited disease development in a rodent rheumatoid arthritis (RA) model. Supporting information for this article is available on the WWW under http://www.wiley-vch.de/contents/jc_2452/2007/z600221_s.pdf or from the author. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Related Papers

• → Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)(2013)217 cited
• → Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?(2023)4 cited
• → Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction.(1994)171 cited
• → Development of btk Transgenic Mice(1995)7 cited
• Molecular studies on Burton's tyrosine kinase(1999)